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Abstract
Background: The incidence of rheumatoid arthritis (RA) is expected to increase over the next 10 years in the European
Union because of the increasing proportion of elderly people. As both RA and ageing are associated with emerging
comorbidities such as cardiovascular disease, malignancies and osteoporosis, these factors will have a profound effect
on the management of RA. In addition, both increasing age and comorbidities may independently alter commonly
used RA-specific outcome measures.
Discussion: Age-related decline in immune cell functions (immunosenescence), such as a decrease in T-cell function,
may contribute to the development of RA, as well as comorbidity. The chronic immune stimulation that occurs in RA
may also lead to premature ageing and comorbidity. The interplay between RA, ageing and (emerging) comorbidities
is interesting but complex. Cardiovascular disease, lung disease, malignancies, bone and muscle wasting and
neuropsychiatric disease all occur more frequently in RA patients as compared to the general population. It is unclear
how RA should be managed in ‘today’s world of multiple comorbidities’. Evidence that treatment of RA improves
comorbidities is currently lacking, although some promising indirect observations are available. On the other hand,
there is limited evidence that medication regularly prescribed for comorbidities, such as statins, might improve RA
disease activity. Both ageing and comorbidity have an independent effect on commonly used outcome measures in
the RA field, such as the Health Assessment Questionnaire (HAQ) and the clinical disease activity index (CDAI).
Prospective studies, that also account for the presence of comorbidity in (elderly) RA patients are therefore urgently
needed. To address gaps in knowledge, future research should focus on the complex interdependencies between RA,
ageing and comorbidity. In addition, these findings should be integrated into daily clinical practice by developing and
testing integrated and coordinated health care services. Adaptation of management recommendations is likely required.
Summary: The elderly RA patient who also deals with (emerging) comorbidities presents a unique challenge to treating
clinicians. A paradigm shift from disease-centered to goal-oriented approach is needed to develop adequate health care
services for these patients.
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Background
By 2030, about one in four inhabitants of the European
Union will be above the age of 65 [1]. The relevance of
ageing is becoming more and more apparent in industri-
alized countries as, in parallel to an increase in life
expectancy, birth rates are decreasing [1]. In an ageing
population, it is expected that the number of patients
with inflammatory arthritis, including rheumatoid
arthritis (RA), will grow proportionally. RA is known to
have a high disease burden and is associated with a sub-
stantial economic burden on patients, their families, and
society [2, 3]. It is estimated that in England the annual
direct healthcare costs of RA are approximately €780
million per year and the indirect costs related to work
disability up to €6.75 billion per year [4]. A considerable
proportion of these costs is due to the fact that RA is a
complex disease associated with an increased prevalence
of several comorbidities [5, 6]. These comorbidities can
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precede or accompany RA, and can be caused by the
therapeutic armamentarium used in patients with RA.
Substantial evidence indicates that the continuous sys-
temic inflammation and immune dysfunction characteris-
tic for RA plays a critical role in the development and
acceleration of comorbidities [7]. Comorbidities most fre-
quently seen in patients with RA include cardiovascular
disease, lung disease, malignancies, osteoporosis, changes
in body composition and neuropsychiatric disease. Most
of these comorbidities occur more frequently than ex-
pected in RA patients as compared to the general popula-
tion. As the number of comorbidities increase with age,
and as patients with RA survive longer, more patients with
RA will have comorbidities. Currently, the average patient
with RA has two or more comorbid disorders [6, 8, 9].
Resolving the interplay between RA, comorbidities and
its determinants is challenging. While the occurrence of
(emerging) comorbidities is more common in RA, the
clinical consequences of comorbidity are also more se-
vere in these patients as compared to controls. Despite
this observation, comorbidity is often underrecognized
and undertreated [6, 10, 11]. Many guidelines and out-
come measures for RA focus on RA as a single disease
and disregard that presence of comorbidity is nowadays
the rule and not the exception.
Future research is therefore urgently needed. However,
to facilitate the identification of knowledge gaps, it is
important to reflect on what is currently known. This
narrative overview will first address the process of ageing
and immuno-senescence in patients with RA. Next,
existing data on the role of RA or its management on
the occurrence or course of comorbidities is summa-
rized. In the following part, literature on implications of
ageing and comorbidities on outcome assessment and
management of RA is presented. If available, results of
meta-analyses or systematic reviews are presented. In
the last part, it is shown how treatment for RA may
positively influence comorbidity and how treatment of
comorbidity may positively influence RA. We will show
that research addressing this topic has been scattered
across multiple disciplines and a solid evidence base
upon which to build policy is currently lacking. To keep
up with the continuing demographic shift of an ageing
(RA) population, we need to expand our knowledge on
ageing and emerging comorbidities in patients with RA
in order to develop adequate health care services for
these patients (Fig. 1).
Discussion
Rheumatoid arthritis, ageing and immunosenescence
To understand how ageing may affect RA and vice versa,
one should first understand the contribution of the
underlying cellular mechanisms. Senescence is a normal
biological process that occurs in all organisms and
involves the age-related decline in cell functions. In the
context of the ageing immune system, this phenomenon
is known as immunosenescence [12]. The mechanisms
behind this process are multidimensional, but key
features include age-related changes in both the adaptive
and innate immune system. Immunosenescence of the
adaptive immune system is characterized by loss of
regenerative capacity and defects in T and B cell produc-
tion, maturation and function (Fig. 2) [12–15]. Most
profoundly, the ability to activate T cells in a productive
manner is decreased. Because of the absence of an ad-
equate T cell activation, the differentiation and effector
function of B cells is also hindered [15, 16].
In addition to loss of effectiveness of the adaptive
immune system, immunosenescence is also character-
ized by an enhanced chance to develop autoimmune
disorders, including RA [16, 17]. The co-occurrence of de-
clining immunocompetence and increasing autoimmune
susceptibility appears contradictory at first sight. There are
however parallels. It is suggested that the lack of immune
Fig. 1 Conceptual model for the effects of ageing and development of
comorbidity in patients with RA. Abbreviation: RA, rheumatoid arthritis
Fig. 2 The interplay between immunosenescence and development
of rheumatoid arthritis [15–17]. Abbreviations: RA, rheumatoid arthritis;
TNF, Tumor Necrosis Factor; IL-6, Interleukin-6; CRP, C-reactive protein
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system stability predisposes to tolerance failure [12, 13]. For
instance, CD28 deficiency in CD4 T-cells is associated with
an increased production of proinflammatory cytokines [14].
In addition, alterations in the innate immune system cause
monocyte and subsequent macrophage activation, resulting
in an increase in levels of Tumor Necrosis Factor (TNF),
Interleukin-6 (IL-6), C-reactive protein (CRP) and other in-
flammatory substances (Fig. 2) [12, 17]. This proinflamma-
tory environment may, together with the development of
self-reactive T and B cells, promote the development of RA.
Alternatively, the continuous systemic inflammation in
established RA may induce accelerated immunosenescence
and development of other morbidities, such as cardiovascu-
lar disease (CVD) and cachexia (Fig. 2) [12, 17, 18].
Rheumatoid arthritis and presence of comorbidity
Cardiovascular disease
CVD usually encompasses coronary heart disease, periph-
eral vascular disease, cerebrovascular disease and congest-
ive heart failure. It might also include prognostic markers
of disease such as hypertension or dyslipidemia. The
association of RA with accelerated atherosclerosis and
eventually cardiovascular disease is a well-established one.
The combined risk of cardiovascular morbidity is doubled
in RA patients and there is a 60 % increase in risk of
cardiovascular mortality [19–23]. In a meta-analysis of
14 observational studies including 41.490 RA patients
by Avina-Zubieta et al., the risk of a myocardial in-
farction and cerebrovascular accident were increased
by almost 70 % (pooled Relative Risk (RR) 1.7 (95 %-CI
1.4-2.0)) and 41 % (pooled RR 1.4 (95 %-CI 1.1-1.7)),
respectively [20].
The RA-associated increased risk of cardiovascular
morbidity and mortality can be explained by several pro-
cesses that often occur simultaneously: (1) the effect of
RA itself due to the presence of chronic systemic inflam-
mation, (2) the effect that the presence of RA modulates
important traditional cardiovascular risk factors or (3)
the use of RA-specific medication such as non-steroidal
anti-inflammatory drugs (NSAIDs), corticosteroids and
disease modifying anti-rheumatic drugs (DMARDs) [5].
Smoking, hypertension, insulin resistance, physical
inactivity, dyslipidaemia and obesity are highly prevalent
in people with RA as compared to the general popula-
tion [24]. A recent meta-analysis suggested that the risk
of cardiovascular events is increased when patients with
RA frequently use corticosteroids ((RR) 1.5; 95 %-CI 1.3-
1.6; p < 0.001) and NSAIDs (RR 1.2; 95 %-CI 1.0-1.4;
p = 0.04) [25]. Interestingly, in a study by Lindhardsen
et al., based on approximately 10 000 patients with RA,
the risk of a myocardial infarction in patients with RA was
similar to the risk of MI in patients without RA who were
10 years older [26].
Lung disease
Interstitial lung disease (ILD) and pleuritis are one of
the most common extra-articular manifestations of RA
[27]. In addition, lung disease may also be related to
drug therapy used in RA or related to other comorbid
disorders. ILD is the most important pulmonary mani-
festation of RA. Bongartz et al. found in a longitudinal
study of 582 RA patients and 603 non-RA individuals,
that the lifetime risk of developing ILD was 7.7 % for
RA patients and 0.9 % for non-RA individuals (HR 9.0
(95 %-CI 4.0-19.9)) [28]. The association between
Chronic Obstructive Pulmonary Disease (COPD), and
RA is less well established [29]. In a meta-analysis of
Ungprasert et al., that included 4 retrospective cohort
studies (32.675 RA patients and 122.204 controls), the
pooled RR of incident COPD in RA patients versus
controls was 2.0 (95 %-CI 1.6-2.5) [29]. However,
confounding might be responsible for the association
between COPD and RA as smoking is also a well-
established risk factor for RA [29].
Malignancies
In a meta-analysis including a total of 21 studies, RA
was an independent risk factor for the development of
lymphoma and was associated with a lymphoma risk
that is approximately two-fold increased (standardized
incidence ratio (SIR) 2.1, 95 %-CI 1.8-2.4) [30]. The risk
on lymphoma appears to be especially higher in patients
with high RA disease activity and presence of rheuma-
toid factor [31, 32]. There seemed to be a decreased risk
for colorectal cancer (SIR 0.8, 95 %-CI 0.7-0.9) [30]. In a
retrospective population cohort study among 84.475 RA
patients who were observed for 405.540 person-years, it
was found that RA patients had a significant higher risk
of developing lung (SIR 1.7, 95 %-CI 1.5-1.8), liver (SIR
1.9, 95 %-CI 1.3-2.6), and oesophageal cancer (SIR 1.8,
95 %-CI 1.2-2.5), but a lower risk of prostate (SIR 0.7,
95 %-CI 0.6-0.7), breast (SIR 0.6, 95 %-CI 0.6-0.7) and
ovarian cancer (SIR 0.6, 95 %-CI 0.5-0.8) cancer [33].
A recent systematic review of 49 studies showed that
RA patients who used a TNF-inhibitor did not have an
additional increased risk for malignancies in general, nor
for lymphoma or non-melanoma skin cancer as com-
pared to RA patients who did not use a TNF-inhibitor.
However, the risk of melanoma might be increased
(adjusted Hazard Ratio (HR) 1.5 (95 % CI 1.0-2.2)) [34].
Osteoporosis and changes in body composition
Another important group of RA associated comorbidi-
ties include bone and muscle wasting. Osteoporosis is
characterized by a decline in bone mineral density
(BMD), which may eventually increase the chance of de-
veloping fragility fractures [35]. The lifetime fracture risk
of a patient with osteoporosis is as high as 40 % [35]. In
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a study that included more than 30.000 RA patients
selected from the British General Practice Research
Database, the RR of a hip fracture was 2.0 (95 %-CI
1.8-2.3) and 2.4 (95 %-CI 2.0-2.8) for a vertebral
fracture [36].
Cachexia due to systemic inflammation is characterized
as the involuntary reduction in lean body mass (LBM)
while fat mass tends to be maintained or even in-
creased so that the body mass index (BMI) remains
stable [37–40]. It has been shown that low LBM and
higher fat mass is associated with a low BMD, even
after controlling for potential confounders such as
age, race, sex, height and grip strength [41, 42].
Specifically, He et al. showed among 17.891 individ-
uals, that those with sarcopenia were two times more
likely to have osteopenia or osteoporosis as compared
to subjects without sarcopenia (OR 2.0; 95 %-CI = 1.6-
2.6) [42]. The prevalence of cachexia in RA patients
highly varies between patient populations and preva-
lence rates between 26-71 % have been reported [39].
The increase in fat mass is suggested to be a risk fac-
tor for the development of the metabolic syndrome
and cardiovascular disease [40]. However, there are
currently no studies that analysed cachexia in relation
to cardiovascular mortality in RA.
Cognitive impairment, depression and anxiety
A few small-size studies have evaluated the impact of
cognitive impairment in patients with RA [43–46].
These studies suggest that cognitive impairment is more
frequently observed in patients with RA as compared to
controls [43, 44]. In one long-term population-based
study of Wallin et al., RA in midlife was associated with
cognitive impairment two decades later, even when cor-
recting for concomitant cardiovascular disease (OR (95 %-
CI): 2.7 (1.2–6.1)) [47]. In another study that did not in-
clude a control group, an impairment in visual-spatial
tasks was detected in 71 % of 30 included patients [44].
Cognitive impairment is also associated with more func-
tional limitations, pain and depression in patients with RA
[46, 48]. Potential risk factors for cognitive impairment
are educational level, income, oral glucocorticoid use and
presence of CVD risk factors [45].
Depression and anxiety are highly prevalent in patients
with RA and are associated with poorer RA outcomes
[49]. In the United States, the 12-months prevalence
estimates of depression and anxiety disorders in the
general population were 6.6 % and 18.1 %, respectively
[50, 51]. Especially the prevalence of depression is
considerably higher in RA patients. In a meta-analysis
that included 13.189 patients with RA from 72 studies,
the prevalence of a major depressive disorder was found
to be 16.8 % (95 %-CI 10 %-24 %) [52]. The prevalence
of anxiety disorders in patients with RA varied between
studies from 13 % to 22 % [53, 54].
Effect of ageing and comorbidities on RA-specific outcome
measures
The functional status of a patient with RA and response
to treatment is measured by several disease-specific out-
come measures, such as the Disease Activity Score −28
(DAS28), Health Assessment Questionnaire (HAQ) and
the American College of Rheumatology (ACR) remission
criteria [55–57]. These outcome measures are often used
in randomised controlled trials (RCTs). The inclusion of
patients in these RCTs is however restricted by stringent
criteria. Therefore, patients included in RCTs often not
resemble the spectrum of patients treated in the ‘real
world’, i.e. elderly patients who often face comorbidity
and polypharmacy.
Notwithstanding, several studies suggest that both age-
ing and comorbidity may independently alter commonly
used RA-specific outcome measures, including joint
scores, remission and response criteria and functional
disability assessments [58–66]. In a population study of
Krishnan et al. among 1530 adults in Finland, 76 % re-
ported some pain and 83 % reported less than perfect
general health. The overall mean value of the Visual
Analogue Scale (VAS) pain was 20 mm [63]. Ageing was
an independent predictor for higher scores on both the
pain VAS and global assessment VAS in this study [63].
Sokka et al. concluded that only 15 % of the general
population > 50 years old meet all four ACR remission
criteria [64]. This finding suggests that the current
remission criteria may not accurately identify remission
in elderly patients. Ranganath et al. evaluated 1584 RA
patients in a prospective cohort study and found that in-
creasing numbers of comorbidities were independently
correlated with less improvement in the clinical disease
activity index (CDAI) after initiation of anti-rheumatic
treatment [58]. The improvement in CDAI was 3.9 units
greater in patients with three or fewer comorbidities as
compared with patients with nine or more comorbidities
[58]. In a study that included 380 RA patients by Radner
et al., it was concluded that increasing levels of comor-
bidities are associated with increasing levels of disability
within each domain of the HAQ [66].
Implications of ageing and comorbidity for
treatment of RA
Rheumatologists’ perspectives on elderly patients with
RA and comorbidity
Nowadays, intensive anti-rheumatic treatment strategies
that adhere to the treat-to-target principle are used to
treat patients with RA [67]. Several studies have however
described the phenomenon of ‘age bias’ when treating
elderly patients with RA. Age bias may eventually result
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in initiation of less intensive treatment regimens [68,
69]. In a study by Kremers et al., younger patients with
RA were significantly more likely to receive DMARDs at
an early stage (HR per 10-year decrease in age 1.4; 95 %-
CI 1.3-1.5) as compared to their older counterparts [68].
Even when the level of disease activity and number of
comorbidities were comparable between younger and
older patients, rheumatologists still preferred the less
intensive treatment option in older patients [68].
By using data from the CORRONA registry Tutunctu
et al. found that the percentage of younger RA patients
who were on DMARD combination therapy (40.5 %) or
on TNF-inhibitors (33.1 %) was considerably higher than
that of older RA patients (30.9 % and 25.0 %, respect-
ively; p < 0.001) [70].
Modification of shared lifestyle risk factors
Smoking cessation, promoting physical activity and
maintaining a healthy body weight are all pivotal
steps to reduce both the prevalence and severity RA,
several comorbidities (e.g. CVD) and to reduce overall
mortality [71–73].
Cigarette smoking significantly increases the risk of
developing RA [74, 75]. In a meta-analysis of observa-
tional studies, the OR to be diagnosed with RA in males
with 20 or more pack-years of smoking was 2.3 (95 %-
CI: 1.6-3.4) [74]. Although the exact mechanism behind
this effect remains uncertain, the process of citrullina-
tion is considered to be an important factor for the
development of RA in the anti-citrullinated protein anti-
body (ACPA)-positive patients [75]. Whether (cessation
of ) smoking influences the disease course in patients
with RA remains controversial. There is no clear associ-
ation between smoking and HAQ, DAS28, CRP or the
erythrocyte sedimentation rate (ESR) [71, 76, 77]. In a
meta-analysis that combined the radiographic data of six
cohorts it was concluded that smoking was not an inde-
pendent risk factor for radiological progression in RA,
but that the effect was mediated via ACPA [78].
Regular exercise training in patients with RA is associ-
ated with improvement of and functional ability (e.g.
aerobic fitness and muscle strength) without exacerbat-
ing disease activity [79–82].
Studies that address the association between body
weight and disease activity show conflicting results and a
high body mass index (BMI) has been correlated with
both higher [83–85] and lower RA disease activity [86].
The European League Against Rheumatism (EULAR)
has formulated recommendations about the need and
timing of cardiovascular risk assessment in patients with
RA [87]. In general, cardiovascular risk assessment
should follow national guidelines (in general be per-
formed annually) [6]. However, currently, no RA-specific
management model is available for risk assessment and
management of cardiovascular disease. According to the
EULAR recommendations, cardiovascular risk prediction
charts (e.g. Framingham Risk Score) should be multiplied
by a factor of 1.5 in case two out of three of the following
criteria are present: (1) disease duration > 10 years; (2)
presence of rheumatoid factor or ACPA; (3) presence of
extra-articular manifestations [87].
Unfortunately, up to our knowledge, there are at this
moment no RCTs that assess the efficacy of antihyper-
tensive agent or statins on cardiovascular endpoints
exclusively in RA patients.
Does treatment of RA improve comorbidities?
The possible beneficial effects of anti-rheumatic treatment
on concomitant cardiovascular disease has not been
addressed in prospective RCTs. As mentioned before,
patients with comorbidities are in fact often excluded
from these RCTs. Most research concentrates on the
question whether anti-rheumatic therapy may prevent the
occurrence of cardiovascular events. Since both RA and
atherosclerosis are inflammatory diseases, anti-rheumatic
therapy may also inhibit various inflammatory pathways
responsible for atherosclerosis. The exact mechanism is
unknown, but beneficial effects on lipoprotein functions
and on macrophage cholesterol metabolism have been
described [88]. A recent meta-analysis of 28 observational
studies suggests that the risk of cardiovascular events can
be decreased by the use of TNF-inhibitors (RR 0.7; 95 %-
CI 0.5-0.9; p = 0.005) and methotrexate (RR 0.7; 95 %-CI
0.6-0.9; p = 0.007) [25].
With regard to osteoporosis it has been suggested that
TNF-inhibitors prevent further generalized bone loss by
inhibiting bone resorption [89]. However, in most of
these short-term and open-label trials, TNF-inhibitors
were combined with methotrexate. Therefore, it needs
to be determined whether this protective effect can be
attributed to use of TNF-inhibitors by itself or the use of
combination therapy and hence better RA disease con-
trol. In addition, no fracture data are currently available
[89]. Interestingly, in early RA, short-term use of gluco-
corticoids may have a positive effect on BMD, due to its
strong anti-inflammatory effects [90]. In a randomized,
placebo-controlled, double-blind 2-year study by van der
Goes et al., addition of 10 mg prednisone daily to a
methotrexate-based tight control strategy did not result
in a negative effect on BMD in early RA patients on
bisphosphonates [90].
Few studies have prospectively examined the impact of
anti-rheumatic treatment on body composition [91–95].
A small-sized randomised study of 21 months duration by
Engvall et al. including 40 patients, the use of TNF-
inhibitors was associated with an increase in body fat mass
(+3.8 (1.6-5.9) kg in the TNF inhibitor group vs +0.4
(−1.5-2.2) kg (p = 0.04) in the conventional synthetic
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DMARD group). There were no changes in muscle mass
or lipid profile [92]. Other studies with a shorter follow-
up duration failed to show a change in body composition
[93–95]. It needs to be determined whether these possible
changes in body composition can be confirmed in other
studies and if so, whether they are associated with devel-
opment of cardiovascular disease on the long term.
In a recent systematic review and meta-analysis, the
effect of TNF-inhibitors on depression and anxiety were
evaluated [96]. Overall, effects were small or not signifi-
cant. However, many studies have shown that anti-
rheumatic therapy improves important patient reported
outcomes including general well-being, fatigue and qual-
ity of life [97].
Does treatment of comorbidities improve RA?
There is some evidence that medication regularly
prescribed for comorbidities, such as statins, might also
improve RA disease activity measures and lower inflam-
matory markers [98, 99]. In addition to their lipid-
lowering effects, statins also exert an anti-inflammatory
function, which is held responsible for the beneficial ef-
fect on RA disease activity. In the randomised, placebo-
controlled Trial of Atorvastatin in Rheumatoid Arthritis
(TARA), it was found that addition of atorvastatin to
standard antirheumatic therapy significantly improved
the DAS28 as compared to placebo (treatment group:
−0.50, 95 %-CI −0.8 to −0.3; placebo group: +0.03, 95 %-
CI −0.2 to 0.3) [99]. In a recent cohort study by Schoen-
feld et al., it was concluded that statin use was inde-
pendently associated with a 21 % lower risk of all-cause
mortality among patients with RA (HR 0.8, 95 %-CI 0.7-
0.9) [99].
There is limited evidence that denosumab, a human
monoclonal antibody against the Receptor activator of
nuclear factor kappa B ligand and used in the treatment
of osteoporosis, may inhibit the development of joint
erosions in patients with RA [100, 101]. However, deno-
sumab had no effect on joint space narrowing or on RA
disease activity [101].
Although selective serotonin reuptake inhibitors have
been reported to exibit anti-inflammatory effects in
addition to their antidepressant effects, there is currently
insufficient evidence that treatment of depression
positively or negatively influences RA disease-specific out-
come measures and other clinical outcomes [102–104]. In
addition, the evidence to routinely prescribe antide-
pressants as analgesics in patients with RA is also
inconclusive [105].
Conclusions
The research to date has successfully identified the
epidemiology of comorbidity in patients with RA, a var-
iety of determinants that influence outcome and to some
extent the consequences associated with the presence of
comorbidity. However, the magnitude of effect of age-
ing and comorbidity on outcome measures and RA
management is largely unknown. Moreover, for many
of the comorbidities, it is equally unclear whether
they should be managed similarly in middle aged ver-
sus older patients. It seems clear that elderly RA pa-
tients who also face comorbidity will need a different
management approach since the needs of these pa-
tients are more than just the sum of needs in relation
to single diseases [106]. The symptoms of RA and co-
morbidities may be overlapping, treatments may inter-
act, underlying pathophysiology may be shared and
the course of all diseases may be altered. As a conse-
quence, the current RA treatment strategies might
not be directly translatable to elderly patients with
RA and comorbidity [107]. Research should focus on
the impact of comorbidities on screening, diagnosis
and outcome measurement of patients with RA.
Nowadays, elderly patients with comorbidities are
often excluded from intervention studies [108]. Future
clinical trials should however take the complex
treatment-reality of these patients into consideration
by developing for instance comprehensive comorbidity
measures in order to correct for confounding and
effect modification in clinical trials [109, 110]. This
may ultimately result in the development of recom-
mendations that can guide the complex management
decisions that need to be made in the case of an age-
ing RA patient who faces comorbidity. In doing so, a
goal-oriented approach should be prioritized above a
disease-centered approach. Maintaining maximal
functional status and active social participation are
essential components of a goal-oriented approach.
Avoiding inefficient healthcare utilisation and medica-
tion side-effects (e.g. suffering more from the treat-
ment than from the disease) is important [111].
We propose the following priority clinical research
areas:
 Improve our understanding on the role of RA and
its management on ageing and occurrence as well
as course of comorbidity.
 Explore barriers within patients and healthcare
providers with regard to (1) prioritization of health
issues and (2) executing a realistic care plan when
dealing with comorbidity;
 Adjusting general and RA-specific outcome measures
that account for ageing and comorbidity;
 Develop, evaluate and implement models for
integrated, coordinated and goal-oriented care.
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